Ast J 2007, 13(six):551?56. 16. Jee KJ, Gong G, Ahn SH, Park JM, Knuutila

Jump to: navigation, search

Wang XC, Tian LL, Tian J, Wu HL, Meng AM: Overexpression of Cks1 is connected with poor survival by Ulation has been rising, there has been little data to suggest inhibiting apoptosis in breast cancer. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D: RAS PubMed ID: oncogenes: weaving a tumorigenic net. Nat Rev Cancer 2011, 11(11):761?74. Ascierto PA, Schadendorf D, Berking C, Agarwala SS, Van Herpen CM, Queirolo P, Blank CU, Hauschild A, Beck JT, St-Pierre A: MEK162 for patients with sophisticated melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase two study. Lancet Oncol 2013, 14:249?56. Posch C, Moslehi H, Feeney L, Green GA, Ebaee A, Feichtenschlager V, Chong K, Peng L, Dimon MT, Phillips T, et al: Combined targeting of MEK and PI3K/mTOR effector pathways is essential to correctly inhibit NRAS mutant melanoma in vitro and in vivo. In Proceedings from the National Academy of Sciences with the United states of america of America. ; 2013. Kulkarni SA, Hicks DG, PubMed ID: Watroba NL, Murekeyisoni C, Hwang H, Khoury T, Beck RA, Ring BZ, Estopinal NC, Schreeder MT, et al: TLE3 as a candidate biomarker of response to taxane therapy. Breast cancer res: BCR 2009, 11(two):R17. Gradishar WJ: Albumin-bound paclitaxel: a next-generation taxane. Professional Opin Pharmacother 2006, 7(eight):1041?053. Desai N, Trieu V, Damascelli B, Soon-Shiong P: SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer individuals. Transl Oncol 2009, two(two):59?four.Ast J 2007, 13(six):551?56. 16. Jee KJ, Gong G, Ahn SH, Park JM, Knuutila S: Achieve in 1q is a common abnormality in phyllodes tumours on the breast. Anal cell pathol: J Euro Society for Anal Cell Pathol 2003, 25(two):89?3. 17. Lu YJ, Birdsall S, Osin P, Gusterson B, Shipley J: Phyllodes tumors in the breast analyzed by comparative genomic hybridization and association of enhanced 1q copy quantity with stromal overgrowth and recurrence. Genes Chromosomes Cancer 1997, 20(three):275?81. 18. Wang XC, Tian LL, Tian J, Wu HL, Meng AM: Overexpression of Cks1 is related with poor survival by inhibiting apoptosis in breast cancer. J Cancer Res Clin Oncol 2009, 135(10):1393?401. 19. Jones AM, Mitter R, Springall R, Graham T, Winter E, Gillett C, Hanby AM, Tomlinson IP, Sawyer EJ, Phyllodes Tumour C: A comprehensive genetic profile of phyllodes tumours from the breast detects essential mutations, intra-tumoral genetic heterogeneity and new genetic changes on recurrence. J Pathol 2008, 214(5):533?44. 20. Perot G, Chibon F, Montero A, Lagarde P, De The H, Terrier P, Guillou L, Ranchere D, Coindre JM, Aurias A: Constant p53 pathway inactivation in aJardim et al. Orphanet Journal of Uncommon Diseases 2013, 8:112 8 of21.22.23. series of soft tissue sarcomas with complex genetics. Am J Pathol 2010, 177(4):2080?090. Gatalica Z, Finkelstein S, Lucio E, Tawfik O, Palazzo J, Hightower B, Eyzaguirre E: p53 protein expression and gene mutation in phyllodes tumors on the breast. Pathol Res Pract 2001, 197(3):183?87.